Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19TNF + Doxorubicin in Advanced Soft Tissue Sarcoma
NCT04032964Phase 1Active, not recruiting
- Sponsor
- Philogen
- Start
- Sep 2019
- Primary completion
- Dec 2024
- Modality
- Antibody Fragments, Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of onfekafusp alfa in soft tissue sarcoma (STS), sponsored by Philogen. Primary endpoints: Number and type of Adverse events (AE), Number and type of Serious Adverse events (SAE) and 3 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
onfekafusp alfa
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04032964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032964.